CompletedNot Applicable

Optimal Allogeneic PRP Concentration for Oocyte In Vitro Maturation in Women With PCOS

Indonesia15 participantsStarted 2023-01-05

Plain-language summary

In vitro maturation is a long-studied technique used to obtain mature oocytes outside the human body. However, this method can increase the risk of ovarian hyperstimulation syndrome (OHSS), particularly in patients with polycystic ovarian syndrome (PCOS). Culture media supplemented with platelet-rich plasma (PRP) has previously shown promise for improving oocyte maturation. This study examined the potential utility of allogeneic PRP supplementation to increase the maturation of germinal vesicle (GV)-stage oocytes collected from PCOS patients who underwent controlled ovarian stimulation. Supplementation with 5% PRP was found to support oocyte maturation under controlled ovarian stimulation. Further investigations are required to refine the use of PRP without controlled ovarian stimulation in clinical IVM protocols that may be beneficial for PCOS patients.

Who can participate

Age range30 Years – 41 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Immature oocytes at the germinal vesicle (GV) stage * Oocytes obtained from patients fulfilling clinical and laboratory diagnostic criteria for PCOS, defined by the presence of at least two of the following three characteristics: clinical hyperandrogenism and/or biochemical hyperandrogenemia, ovulatory dysfunction (oligomenorrhea or anovulation), and polycystic ovarian morphology (≥12 follicles measuring 2-9 mm in each ovary on ultrasonography) * Oocytes collected from patients undergoing ovarian stimulation using the same ovarian stimulation protocol. * Oocytes obtained from patients with primary infertility * Oocytes obtained from treatment-naive patients with PCOS. Exclusion Criteria: \- Oocytes obtained from patients with comorbid conditions, including cancer, congenital adrenal hyperplasia, Cushing's syndrome, premature ovarian failure (POF) or premature ovarian insufficiency, liver disorders, kidney disease, cardiovascular disease, diabetes mellitus (type 1 or type 2), and patients receiving steroid therapy

What they're measuring

Optimal PRP Concentration

Timeframe: After 24 hours of culture incubation

Trial details

NCT IDNCT07514234

SponsorGadjah Mada University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-09-11